阿里健康携手石药集团,首发1类创新药普卢格列汀(善泽平)

动脉网
Oct 13

10月13日,石药集团1类创新药普卢格列汀片(善泽平)在阿里健康首发,该药用于成人2型糖尿病患者的血糖控制。中国T2DM患者众多,且常合并多种疾病需多重用药,但多重用药会带来低血糖风险增加、服药依从性下降等问题。在此背景下,药物相互作用风险小、低血糖发生率低的降糖药成为临床优选。普卢格列汀作为我国自主研发的1类创新DPP-4抑制剂,药物相互作用风险小,且每日一次服用便捷,与主要经过CYP450酶...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10